<DOC>
	<DOC>NCT01874431</DOC>
	<brief_summary>To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it is safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses will be compared to placebo.</brief_summary>
	<brief_title>Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Men and women aged 18 years and older.The lower age limit may be higher if legally required in the participating country Women of childbearing potential can only be included in the study if a pregnancy test is negative and if they agree to use adequate contraception when sexually active. Subjects with type 2 diabetes mellitus fulfilling at least 1 of the following criteria are on oral antidiabetics and / or insulin, have a documented fasting glucose &gt;/= 7.0 mmol/L in the medical history, have a 2 hour plasma glucose &gt;/=11.1 mmol/L during an oral glucose tolerance test in the medical history, or have a glycated hemoglobin (HbA1c) &gt;/=6.5% [National Glycohemoglobin Standardization Program (NGSP) / Diabetes Control and Complications Trial (DCCT)] in the medical history or at the runin visit Subjects with a clinical diagnosis of diabetic nephropathy (DN) based on at least 1 of the following criteria: Persistent very high albuminuria defined as urinary albumintocreatine ratio (UACR) of &gt;/=300 mg/g ( &gt;/= 34 mg/mmol) in 2 out of 3 first morning void samples and estimated glomerular filtration rate (eGFR) &gt;/=30 mL/min/1.73 m² but &lt; 90 mL/min/1.73m² (Chronic Kidney Disease Epidemiology Collaboration, CKD EPI) (mL = milliliter; min = minute; m2 = square meter; g = gram; mmol = millimole) or Persistent high albuminuria defined as UACR of &gt;/=30 mg/g but &lt;300 mg/g in (&gt;/=3.4mg/mmol but &lt;34 mg/mmol) in 2 out of 3 first morning void samples and eGFR &gt;/=30 mL/min/1.73 m² but &lt; 90 mL/min/1.73m² Subjects treated with an angiotensinconverting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) for at least 3 months without any adjustments to this therapy for at least 4 weeks prior to the screening visit Serum potassium &lt;/= 4.8 mmol/L at both the runin visit and the screening visit Nondiabetic renal disease Glycated hemoglobin (HbA1c) &gt;12% at the runin visit or the screening visit UACR &gt;3000 mg/g (339mg/mmol) in any of the urinary first morning void samples at the runin visit or screening visit Hypertension with mean sitting systolic blood pressure (SBP) &gt;/=180 mmHg or mean sitting diastolic blood pressure (DBP) &gt;/=110 mmHg at the runin visit or mean supine SBP &gt;/=160 mmHg or mean sitting DBP &gt;/=100 mmHg at the screening visit Subjects with a clinical diagnosis of heart failure with reduced ejection fraction (HFrEF) and persistent symptoms (New York Heart Association class IIIV) at the runin visit Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or potassiumsparing diuretic Dialysis for acute renal failure within the previous 6 months prior to the runin visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>